Syndax

syndax.com

Syndax Pharmaceuticals is a commercial stage oncology innovator focused on developing first-in-class therapies for significant unmet needs in cancer treatment, particularly in acute leukemia and chronic graft-versus-host disease. The company is committed to scientific excellence and aims to deliver therapeutics that provide meaningful clinical results. Their key products include Revuforj® (revumenib) and axatilimab, with ongoing trials to expand their indications. Syndax's approach emphasizes collaboration and innovation, positioning them as a leader in the oncology space with a strong pipeline and commitment to improving patient outcomes.